公开(公告)号：EP1846451B1

公开(公告)日：2013-05-15

申请号：EP06701099.1

申请日：2006-01-24

申请人： MEDIMMUNE LIMITED ,  Elan Pharma International Limited

发明人： FRANKS, Ruth, Cambridge Antibody Technology Limited ,  BUCHANAN, Andrew Grier, Cambridge Antibody Technology Limited ,  THOM, Albert George, Cambridge Antibody Technology Limited ,  WELSH, Fraser Ewing, Cambridge Antibody Technology Limited ,  BLAND-WARD, Philip Antony, Cambridge Antibody Technology Limited ,  SLEEMAN, Matthew Alexander, Cambridge Antibody Technology Limited ,  MATTHEWS, Carl Anthony, Cambridge Antibody Technology Limited ,  HART, Celia Patricia, Cambridge Antibody Technology Limited ,  HAWKINSON, Jon, Elan Pharmaceuticals, Inc.

IPC分类号： C07K16/22 ,  C07K14/48

CPC分类号： C07K16/22 ,  A61K39/3955 ,  A61K2039/505 ,  C07K14/48 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

公开(公告)号：EP1846451A1

公开(公告)日：2007-10-24

申请号：EP06701099.1

申请日：2006-01-24

申请人： CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED ,  Elan Pharma International Limited

发明人： FRANKS, Ruth, Cambridge Antibody Technology Limited ,  BUCHANAN, Andrew Grier, Cambridge Antibody Technology Limited ,  THOM, Albert George, Cambridge Antibody Technology Limited ,  WELSH, Fraser Ewing, Cambridge Antibody Technology Limited ,  BLAND-WARD, Philip Antony, Cambridge Antibody Technology Limited ,  SLEEMAN, Matthew Alexander, Cambridge Antibody Technology Limited ,  MATTHEWS, Carl Anthony, Cambridge Antibody Technology Limited ,  HART, Celia Patricia, Cambridge Antibody Technology Limited ,  HAWKINSON, Jon, Elan Pharmaceuticals, Inc.

IPC分类号： C07K16/22 ,  C07K14/48

CPC分类号： C07K16/22 ,  A61K39/3955 ,  A61K2039/505 ,  C07K14/48 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

摘要： Specific binding members for Nerve Growth Factor (NGF), in particular anti-NGF antibody molecules, especially human antibody molecules, and especially those that neutralise NGF activity. Methods for using anti-NGF antibody molecules in diagnosis or treatment of NGF related disorders, including pain, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, other diseases of airway inflammation, diabetic neuropathy, cardiac arrhythmias, HIV, arthritis, psoriasis and cancer.